bepirovirsen (GSK3228836) / GSK, Ionis - LARVOL DELTA

An RNA interference therapeutic potentially achieves functional cure of chronic hepatitis B virus infection. (PubMed, Nat Commun) - "Toxicity studies in Sprague-Dawley rats and cynomolgus monkeys indicate satisfactory biosafety profiles of KC13-M2G2. Given that elebsiran and bepirovirsen have achieved a functional cure rate of no more than 20% in their clinical studies, KC13-M2G2 as a more potent candidate drug is expected to exhibit superior performance in clinical applications."

Journal • Hepatitis B • Infectious Disease • Inflammation

Beyond immune activation: unresolved questions in bepirovirsen's mechanism of action toward HBV functional cure. (PubMed, Hepatol Int) - No abstract available

Journal

Comment on 'Immunomodulation by bepirovirsen may induce killing of infected hepatocytes (B-Together study)'. (PubMed, Hepatol Int) - No abstract available

Journal • Immunology

Beyond ALT flares: rethinking immune activation and mechanistic interpretation in bepirovirsen-treated chronic hepatitis B. (PubMed, Hepatol Int) - No abstract available

Journal • Hepatitis B • Infectious Disease • Inflammation

Assessment of Health State Utilities Associated With Treatment for Chronic Hepatitis B Virus (HBV) Infection (ISPOR-EU 2025) - "New treatments, such as bepirovirsen (an unconjugated antisense oligonucleotide currently in Phase 3 studies), are being developed with the goal of functional cure (i.e., long-term HBV surface antigen loss and undetectable HBV DNA after cessation of therapy)... The highest utilities were found for health states describing functional cure and the period immediately preceding functional cure (NA cessation). Health states describing treatment with Peg-IFN had the lowest utilities, possibly due to drug-associated adverse events. Information from this study may be useful in models examining cost-effectiveness of HBV treatments."

Hepatitis B • Hepatology • Infectious Disease • Inflammation

Beyond viral suppression: assessing the immunotherapeutic potential of bepirovirsen for chronic hepatitis B. (PubMed, Hepatol Int) - No abstract available

Journal • Hepatitis B • Infectious Disease • Inflammation

GSK presents data from its advancing liver pipeline at AASLD 2025 (GSK Press Release) - "21 abstracts highlight advances in the treatment of liver conditions, building from GSK’s expertise in inflammation and fibrosis; Phase II B-Sure study sub-analysis shows durability of functional cure in chronic hepatitis B (CHB) patients treated with bepirovirsen and pegylated interferon (Peg-IFN); Late breaking results for once-monthly efimosfermin in metabolic dysfunction-associated steatohepatitis (MASH), supporting the start of phase III clinical trials"

Clinical data • Hepatitis B • Metabolic Dysfunction-Associated Steatohepatitis

Comment on "Immunomodulation by bepirovirsen may induce killing of infected hepatocytes (B-Together study)". (PubMed, Hepatol Int) - No abstract available

Journal • Immunology

A Study on the Safety, Efficacy and Immune Response Following Sequential Treatment With an Anti-sense Oligonucleotide Against Chronic Hepatitis B (CHB) and Chronic Hepatitis B Targeted Immunotherapy (CHB-TI) in CHB Patients Receiving Nucleos(t)Ide Analogue (NA) Therapy (clinicaltrials.gov) - P2 | N=174 | Completed | Sponsor: GlaxoSmithKline | Active, not recruiting ➔ Completed

Trial completion • Hepatitis B • Infectious Disease • Inflammation

A Phase 1, Randomized, Open-Label, Parallel Group Study to Evaluate the Relative Bioavailability and Safety of Subcutaneous Bepirovirsen when Delivered from a Vial or Prefilled Syringe Fitted with a Safety Syringe Device in Healthy Adult Participants. (PubMed, Clin Pharmacol Drug Dev) - P1 | "These findings confirm that PFS SSD is a viable alternative to vials for bepirovirsen administration, when HCP- or self-administered, for the treatment of chronic HBV. Clinical trial identifier: NCT06058390."

Journal • P1 data • Hepatitis B • Infectious Disease • Inflammation

RETROSPECTIVE ANALYSIS OF B-CLEAR STUDY HBSAG LEVELS WITH THE ULTRASENSITIVE LUMIPULSE HBSAG ITACT ASSAY AND ASSOCIATION WITH RESPONSE AND RELAPSE (AASLD 2025) - "Background: Bepirovirsen is an unconjugated antisense oligonucleotide in development for chronic hepatitis B virus (HBV) infection that has been shown to reduce hepatitis B surface antigen (HBsAg). The iTACT HBsAg assay provides additional data with improved resolution to support pharmacokinetic/pharmacodynamic modeling. However, further studies with larger sample sizes and additional time points are needed to confirm the findings. References: 1."

Retrospective data • Hepatitis B • Hepatology • Infectious Disease • Inflammation

A NOVEL MRNA-BASED IMMUNOTHERAPY ACHIEVES COMPLETE ELIMINATION OF HUMAN HEPATITIS B VIRUS IN CHRONIC HBV MOUSE MODELS (AASLD 2025) - " We developed two mRNA-based immunomodulators (IMs) and evaluated their therapeutic potential in combination with entecavir and either a siRNA (Elebsiran) or an ASO (Bepirovirsen) in two distinct chronic HBV mouse models for elimination of HBV both in the periphery and intrahepatic compartment. Combination therapies containing one of the IMs led to a rapid and profound decline in HBsAg and HBV DNA, whereas prophylactic HBV vaccine (Engerix) had minimum impact on these viral markers... Our study demonstrated that either novel IMs, when used in combination with direct antivirals, achieved a rapid, robust, and sustained suppression of HBV infection in chronic mouse models. We observed rapid and sustained declines in HBsAg and HBV DNA in plasma and HBcAg in the liver. Unlike treatments lacking the IMs, which only induced a rapid yet transient HBsAg and HBV DNA decline followed by a rapid rebound of these viral markers once the treatments were discontinued, our approach..."

IO biomarker • Preclinical • Hepatitis B • Hepatitis C • Hepatology • Infectious Disease • Inflammation

PROTEOMIC PROFILING IN PREFILLED SYRINGE STUDY DEMONSTRATES BEPIROVIRSEN'S IMMUNE STIMULATORY EFFECT (AASLD 2025) - P1, P2 | "These data demonstrate that bepirovirsen mediates a strong innate immune response, with the highest activity observed at 24–48 hours, suggesting a sustained immune response that lasts at least 48 hours. The similar immune protein profile changes observed in patients with chronic HBV infection and in healthy volunteers in this study suggests that this immune response is stimulated by bepirovirsen treatment regardless of the presence of HBV. Funding: GSK (219239)"

Hepatitis B • Hepatology • Infectious Disease • Inflammation

TRIPLE-TARGETING IMMUNOMODULATOR C3 TREATMENT PROMOTES HBV CLEARANCE THROUGH FUNCTIONAL RECONSTITUTION OF HOST IMMUNITY IN HBV-CARRIER MOUSE MODELS (AASLD 2025) - "Besides, the combinatorial antiviral efficacy and response maintenance after withdraw of bepirovirsen or siRNA (si1260/1848) with C3 was systematically evaluated in rAAV8-1.3X HBV mouse models... The triple-targeting immunomodulator C3 could eliminate HBV infection and ameliorate the viral rebound via host immune system activation, representing C3 a promising CHB therapeutic candidate."

Immunomodulating • Preclinical • Hepatitis B • Hepatitis C • Hepatology • Infectious Disease • Inflammation

INTRAHEPATIC AND PERIPHERAL IMMUNOPHENOTYPING OF PARTICIPANTS WITH CHRONIC HEPATITIS B RECEIVING BEPIROVIRSEN IN THE B-FINE STUDY STRONGLY SUGGESTS THAT BEPIROVIRSEN MAY TRIGGER A HUMORAL RESPONSE (AASLD 2025) - P2 | "The proteomic, transcriptomic (liver and peripheral) and flow cytometry data obtained from the B-Fine study strongly suggest that bepirovirsen triggers a humoral immune response in treated pts. Three pts achieved HBsAg loss following bepirovirsen treatment. Funding: GSK (212602)"

Hepatitis B • Hepatology • Infectious Disease • Inflammation • CD20 • CD22 • CD80 • CXCR6 • FCRLB • MS4A1

UP TO 12 MONTHS' DURABILITY OF FUNCTIONAL CURE WITH BEPIROVIRSEN PLUS PEG-IFN SEQUENTIAL THERAPY IN B-TOGETHER RESPONDERS: B-SURE STUDY (AASLD 2025) - P2 | "These data provide evidence of the durability of functional cure for up to 1 year in CRs to sequential bepirovirsen plus Peg-IFN therapy. Funding: GSK (206882)"

Hepatitis B • Hepatology • Infectious Disease • Inflammation

INTRAHEPATIC IMMUNOPHENOTYPING OF PARTICIPANTS WITH CHRONIC HEPATITIS B RECEIVING BEPIROVIRSEN IN THE B-FINE STUDY REVEALS DIVERSE CHANGES IN IMMUNOLOGICAL STATUS (AASLD 2025) - P2 | "Variable clinical, virological and immunological responses to bepirovirsen treatment were observed among pts with chronic HBV infection in this study. Overall, repeat FNA sampling captured activation of the immune compartment in the liver, regardless of response. Three pts achieved HBsAg loss following bepirovirsen treatment."

Hepatitis B • Hepatology • Infectious Disease • Inflammation

LEAD OPTIMIZATION AND SELECTION OF A POTENTIAL BEST-IN-CLASS HBV ASO (AASLD 2025) - "Current clinical stage HBV ASOs, bepirovirsen (GSK-836) and AHB-137, are unique in their dual RNase H-mediated direct antiviral and immunomodulatory (e.g. TLR8 agonist) activities. Optimized HBV ASO leads ALG-170675, ALG-171036 and ALG-171191 showed significant potential to be best-in-class HBV ASOs. Further investigations are underway."

Hepatitis B • Hepatology • Infectious Disease • Inflammation • CASP3 • CASP7 • TLR8

Immunomodulation by bepirovirsen may induce killing of infected hepatocytes (B-Together study). (PubMed, Hepatol Int) - P2, P2b | "These findings provide evidence that bepirovirsen may modulate the immune system to facilitate infected hepatocyte killing in chronic HBV infection in addition to its direct antiviral effects; therefore, ALT increases could reflect a therapeutic response to bepirovirsen."

Journal • Hepatitis B • Immunology • Infectious Disease • Inflammation

Emerging Trends and Future Directions in the Development of Anti-hepatitis B Therapies: A Horizon Scanning Review. (PubMed, Clin Drug Investig) - "The robust and diverse pipeline of novel anti-hepatitis B virus treatments offers promise for improving functional cure rates, but definitive conclusions await longer off-treatment follow-up and durability data. Continued research, rational combination strategies, and global collaboration are crucial to overcome challenges and ensure equitable access to these transformative therapies worldwide."

Journal • Review • Hepatitis B • Hepatology • Infectious Disease • Inflammation

B-Kind: A Study to Evaluate Blood Levels of Bepirovirsen in Adult Participants With Severe or Moderate Kidney Disease (clinicaltrials.gov) - P1 | N=32 | Not yet recruiting | Sponsor: GlaxoSmithKline

New P1 trial • Hepatitis B • Infectious Disease • Inflammation • Nephrology • Renal Disease

B-UNITED: A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB) (clinicaltrials.gov) - P2 | N=264 | Active, not recruiting | Sponsor: GlaxoSmithKline | Recruiting ➔ Active, not recruiting

Enrollment closed • Hepatitis B • Infectious Disease • Inflammation

Study of GSK3965193 in Healthy Participants and Participants Living With Chronic Hepatitis B Infection (clinicaltrials.gov) - P1/2 | N=74 | Active, not recruiting | Sponsor: GlaxoSmithKline | Recruiting ➔ Active, not recruiting | Trial completion date: Sep 2027 ➔ Apr 2026 | Trial primary completion date: Sep 2027 ➔ May 2025

Enrollment closed • Monotherapy • Trial completion date • Trial primary completion date • Hepatitis B • Infectious Disease • Inflammation

Advancing HIV cure: insights from developing chronic hepatitis b therapies for functional cure. (PubMed, Curr Opin HIV AIDS) - "Given the persistence of cccDNA and integrated DNA, together with HBsAg-induced immune dysfunction, successful treatment for CHB to induce FC is likely to require a combination of agents that inhibit viral replication, reduce HBsAg levels, and boost the antiviral immune response."

Journal • Review • Hepatitis B • Human Immunodeficiency Virus • Infectious Disease • Inflammation • IFNA1

Study of GSK3965193 in Healthy Participants and Participants Living With Chronic Hepatitis B Infection (clinicaltrials.gov) - P1/2 | N=84 | Recruiting | Sponsor: GlaxoSmithKline | Trial completion date: Jan 2027 ➔ Sep 2027 | Trial primary completion date: Jan 2027 ➔ Sep 2027

Trial completion date • Trial primary completion date • Hepatitis B • Infectious Disease • Inflammation